Josefin Skogsberg
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
PIEZO1 targeting in macrophages boosts phagocytic activity and foam cell apoptosis in atherosclerosis.
Journal: Cellular and molecular life sciences : CMLS
Published: March 06, 2024
Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital-based care, days absent from work, costs and mortality.
Journal: Diabetes, obesity & metabolism
Published: August 10, 2022
Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease.
Journal: Diabetes, obesity & metabolism
Published: August 10, 2022
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
Journal: Diabetes, obesity & metabolism
Published: July 13, 2022
Plaque Evaluation by Ultrasound and Transcriptomics Reveals BCLAF1 as a Regulator of Smooth Muscle Cell Lipid Transdifferentiation in Atherosclerosis.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: March 24, 2022
Induction of the Coxsackievirus and Adenovirus Receptor in Macrophages During the Formation of Atherosclerotic Plaques.
Journal: The Journal of infectious diseases
Published: April 15, 2020
Correction to: Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits.
Journal: BMC medical genomics
Published: November 06, 2019
Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits.
Journal: BMC medical genomics
Published: July 27, 2019
Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
Journal: Neurobiology of aging
Published: June 14, 2019
Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.
Journal: Acta neuropathologica communications
Published: February 12, 2018
Last Updated: 09/26/2026